发明名称 |
Method of treating cognitive impairments and schizophrenias |
摘要 |
The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1);
wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond. |
申请公布号 |
US9089567(B2) |
申请公布日期 |
2015.07.28 |
申请号 |
US201113303265 |
申请日期 |
2011.11.23 |
申请人 |
Otsuka Pharmaceutical Co., LTD. |
发明人 |
Jordan Shaun;Kikuchi Tetsuro;Tottori Katsura;Hirose Tsuyoshi;Uwahodo Yasufumi |
分类号 |
A61K31/496;A61K45/06 |
主分类号 |
A61K31/496 |
代理机构 |
Finnegan, Henderson, Garrett & Dunner, LLP |
代理人 |
Finnegan, Henderson, Garrett & Dunner, LLP |
主权项 |
1. A method of treating a patient suffering from treatment-resistant schizophrenia,
comprising administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof: wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond, wherein the patient is a mammal and the patient fails to respond adequately to antipsychotic drugs which are at least one typical antipsychotic drug and at least one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride. |
地址 |
Tokyo JP |